Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AGAP11, annotated as "ArfGAP with GTPase domain, ankyrin repeat and PH domain 11," is classified as a non-coding RNA (ncRNA) gene and not as a protein-coding gene, despite its name suggesting a possible functional protein. Although its name groups it with ArfGAP family members (proteins involved in GTPase regulation and vesicular trafficking), current evidence indicates AGAP11 does not encode a functional protein and is primarily classified under the ncRNA class[1][3]. Functional annotation data only predict possible GTPase activator activity, but this is based on its sequence similarity, not experimental validation[1]. There are no known molecular, biological, or pharmacological targets or disease associations for AGAP11, and it should not be considered a therapeutic target. Key points: - AGAP11 is a non-coding RNA gene, not a functional protein-coding gene. - The name is potentially misleading; it is not a validated member of the druggable ArfGAP protein family. - No established biological functions, disease relevance, or pharmacological data exist for AGAP11 at this time[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ArfGAP with GTPase domain, ankyrin repeat and PH domain 11 (AGAP11).